American Association for Cancer Research

Program

Bookmark and Share


*Program subject to change (updated January 10)

Saturday, January 18

Opening Plenary Session

7:00 p.m.-9:00 p.m.

Targeting PI3K for cancer therapy
Lewis C. Cantley, The Cancer Center at Weill Cornell Medical College and New York-Presbyterian Hospital, New York, NY

Prostate cancer epidemiology in the PSA era: The imperative to focus on lethal disease
Meir J. Stampfer, Harvard School of Public Health, Boston, MA

Opening Reception

9:00 p.m.-10:30 p.m.

 

Sunday, January 19

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 1: Obesity, Exercise, Metabolism, and Aggressive Prostate Cancer

Session Chairperson: June M. Chan, University of California, San Francisco, CA
8:00 a.m.-10:00 a.m.

Metabolic aspects of prostate cancer
Michael N. Pollak, Jewish General Hospital, Montreal, QC, Canada

Obesity, its sequelae, and prostate cancer risk and outcomes
Elizabeth A. Platz, Johns Hopkins University, Baltimore, MD

The role of metabolism in prostate cancer
Matthew G. Vander Heiden, MIT Koch Institute for Integrated Cancer Research, Cambridge, MA

Break

10:00 a.m.-10:30 a.m.

Plenary Session 2: Can Prostate Cancer Be Prevented?

Session Chairperson: Peter H. Gann, University of Illinois, Chicago, IL
10:30 a.m.-12:30 p.m.

Forging ahead with prostate cancer prevention
Peter H. Gann

Chemopreventive agent development for prostate cancer: Is there a future?
Maarten C. Bosland, University of Illinois, Chicago, IL

Fish oil, omege-3 fatty acids, and prostate cancer
William J. Aronson, University of California – Los Angeles, Los Angeles, CA

Discussant: Meir J. Stampfer, Harvard School of Public Health, Boston, MA

Lunch Break

(Lunch on your own; poster set-up and viewing available.)

12:30 p.m.-2:30 p.m.

Plenary Session 3: Genetic Susceptibility to Prostate Cancer: From Rare to Common Variants

Session Chairperson: Kathleen A. Cooney, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
2:30 p.m.-4:30 p.m.

Rare penetrant prostate cancer genes (BRCA1,2 and HOXB13)
Kathleen A. Cooney

Genetic risk for prostate cancer in racially diverse populations
John S. Witte, University of California, San Francisco, CA

Current status of common prostate cancer risk-associated SNPs and their potential clinical utilities
Jianfeng Xu, Wake Forest School of Medicine, Winston-Salem, NC

Short Talks from Proffered Papers

Session Chairperson: Howard R. Soule, Prostate Cancer Foundation, Santa Monica, CA
4:45 p.m.-5:25 p.m.

Monitoring copy number aberration dynamics in sequential plasma samples from castration-resistant prostate cancer (CRPC) patients
Gerhardt Attard, The Institute of Cancer Research and the Royal Marsden, Sutton, Surrey, United Kingdom

Frequency and characterization of circulating tumor cell (CTC) populations in metastatic castration-resistant prostate cancer (mCRPC)
Ryan Dittamore, Epic Sciences, Inc., La Jolla, CA

Development and validation of a lifestyle score for prevention of lethal prostate cancer
Stacey A. Kenfield, University of California - San Francisco, San Francisco, CA

Urinary melatonin levels, sleep disruption, and risk of prostate cancer
Sarah C. Markt,  Harvard School of Public Health, Boston, MA

PTEN loss together with ERG overexpression correlates with shorter survival after radical prostatectomy
Andrew Erickson, Institute for Molecular Medicine Finland, Helsinki, Finland

Coordinate induction of autophagy and apoptosis by wildtype p53 in prostate cancer cells
Chris Albanese, Georgetown University Medical Center, Washington, DC

Patient-specific kinase activation patterns in lethal metastatic castration-resistant prostate cancer
Justin M. Drake, University of California - Los Angeles, Los Angeles, CA

Poster Session A

5:30 p.m.-7:30 p.m.

 

Monday, January 20

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 4: Precision Medicine: Decision to Treat or Not Treat

Session Chairperson: Peter R. Carroll, University of California – San Francisco, San Francisco, CA
8:00 a.m.-10:00 a.m.

Prostate cancer: To treat or not to treat – Why is this an important question?
Peter R. Carroll

A multi-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling
Eric A. Klein, The Cleveland Clinic Lerner Research Institute, Cleveland, OH

Can biomarkers guide decisions about active surveillance versus immediate treatment?
Matthew R. Cooperberg, University of California, San Francisco, CA

Long noncoding RNAs: What you didn't learn during your postdoc
Felix Feng, University of Michigan, Ann Arbor, MI

Break

10:00 a.m.-10:20 a.m.

Plenary Session 5: Toward Better Models of Prostate Cancer

Session Chairperson: Owen N. Witte, University of California – Los Angeles, Los Angeles, CA
10:20 a.m.-12:20 p.m.

Starting and stopping prostate cancer in stem cells
Owen N. Witte

Using cross-species analysis of genome-wide regulatory networks to identify drivers of prostate cancer malignancy
Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY

Using MYC overexpression and PTEN loss in mouse models of prostate cancer
Angelo M. De Marzo, The Johns Hopkins University School of Medicine, Baltimore, MD

Title to be announced
Peter Kuhn, The Scripps Research Institute, LaJolla, CA

Short Talks from Proffered Papers

Session Chairperson: Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI
12:20 p.m.-12:55 p.m.

A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer
Akash Patnaik, Beth Israel Deaconess Medical Center, Boston, MA

Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells
Tanya I. Stoyanova, University of California – Los Angeles, Los Angeles, CA

CpG-STAT3 siRNA for therapy of castration-resistant prostate cancers
Marcin Kortylewski, City of Hope, Duarte, CA

Immune evasion strategies of neuroendocrine-like enzalutamide-resistant prostate cancer
Jennifer L. Bishop, Vancouver Prostate Centre, Vancouver, BC, Canada.

Mechanisms of clonal progression from Gleason 3 to Gleason 4 prostate cancer
Adam G. Sowalsky, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Poster Session B / Lunch

1:00 p.m.-3:00 p.m.

Plenary Session 6: Anti-Androgen Sensitivity and Resistance During Prostate Cancer Progression

Session Chairperson: Nima Sharifi, The Cleveland Clinic, Cleveland, OH
3:00 p.m.-5:00 p.m.

Opening the floodgates to DHT synthesis sustains resistance to androgen depletion
Nima Sharifi

Epigenetic targets in castration-resistant prostate cancer
Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA

AR-DNA repair interplay in prostate cancer: Mechanisms and implications for disease progression
Karen E. Knudsen, Thomas Jefferson University/Kimmel Cancer Center, Philadelphia, PA

Emerging developments in abiraterone resistance
Steven P. Balk, Beth Israel Deaconess Medical Center, Boston, MA

Point/Counterpoint Session: Can Treatment Targeted at the Androgen Signaling Pathway Ever Cure Prostate Cancer?

Moderator: Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA
5:05 p.m.-6:05 p.m.

    Panelists:
  • Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA

 

Tuesday, January 21

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 7: Precision Medicine: How Much Can We Further Personalize Prostate Cancer Treatment?

Session Chairperson: Himisha Beltran, Weill Cornell Medical College of Cornell University, New York, NY
8:00 a.m.-10:00 a.m.

Grasping the tails of precision medicine
Himisha Beltran

Towards precision medicine for advanced prostate cancer
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

Precision medicine: How much can we further personalize prostate cancer treatment?
Eric Small, University of California, San Francisco, CA

Break

10:00 a.m.-10:15 a.m.

Closing Plenary Session

10:15 a.m.-11:15 a.m.

Prostate cancer landscape 2014: The emperor of all research opportunities
Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA

Departure

11:15 a.m.